1. Home
  2. AIEV vs EQ Comparison

AIEV vs EQ Comparison

Compare AIEV & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIEV
  • EQ
  • Stock Information
  • Founded
  • AIEV 2011
  • EQ 2017
  • Country
  • AIEV United States
  • EQ United States
  • Employees
  • AIEV N/A
  • EQ N/A
  • Industry
  • AIEV Blank Checks
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIEV Finance
  • EQ Health Care
  • Exchange
  • AIEV Nasdaq
  • EQ Nasdaq
  • Market Cap
  • AIEV 25.8M
  • EQ 24.8M
  • IPO Year
  • AIEV N/A
  • EQ 2018
  • Fundamental
  • Price
  • AIEV $0.29
  • EQ $0.72
  • Analyst Decision
  • AIEV
  • EQ Buy
  • Analyst Count
  • AIEV 0
  • EQ 2
  • Target Price
  • AIEV N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • AIEV 116.1K
  • EQ 304.3K
  • Earning Date
  • AIEV 11-14-2024
  • EQ 11-13-2024
  • Dividend Yield
  • AIEV N/A
  • EQ N/A
  • EPS Growth
  • AIEV N/A
  • EQ N/A
  • EPS
  • AIEV N/A
  • EQ N/A
  • Revenue
  • AIEV N/A
  • EQ $45,914,000.00
  • Revenue This Year
  • AIEV N/A
  • EQ N/A
  • Revenue Next Year
  • AIEV N/A
  • EQ N/A
  • P/E Ratio
  • AIEV N/A
  • EQ N/A
  • Revenue Growth
  • AIEV N/A
  • EQ 7.70
  • 52 Week Low
  • AIEV $0.27
  • EQ $0.48
  • 52 Week High
  • AIEV $12.12
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • AIEV N/A
  • EQ 40.86
  • Support Level
  • AIEV N/A
  • EQ $0.66
  • Resistance Level
  • AIEV N/A
  • EQ $0.77
  • Average True Range (ATR)
  • AIEV 0.00
  • EQ 0.08
  • MACD
  • AIEV 0.00
  • EQ -0.01
  • Stochastic Oscillator
  • AIEV 0.00
  • EQ 26.09

About AIEV Thunder Power Holdings Inc. Common Stock

Thunder Power Holdings Inc is engaged in the design and development of high-performance electric vehicles.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: